Company profile
Damora Therapeutics, Inc.
NASDAQ: DMRA · Healthcare · Biotechnology
#1 of 1,418 Healthcare companies by revenue
EA Score
——FH 63DQ —GM —SS 37
v0.1 · 35/100 weight · pillars only
↑ Altman-Z, balance-sheet leverage · ↓ listing tenure, workforce scale
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$209.8M
Employees
7
as of 2026-08-09
Market cap
$1.8B
as of 2026-08-09
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Net income-$209.8M-$209.8M2025
Operating income-$210.9M-$210.9M2025
Total assets$260.5M$260.5M2025
Liabilities$20.1M$20.1M2025
Equity$240.4M$240.4M2025
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Damora Therapeutics, Inc.’s financial profile?
Damora Therapeutics, Inc. earned -$209.8M in FY2025 net income.
Peers · Healthcare
Kailera Therapeutics, Inc.——Rapport Therapeutics, Inc. Common Stock——Braveheart Bio, Inc.——Generate Biomedicines, Inc.——Tyra Biosciences, Inc.——Bicara Therapeutics Inc. Common Stock——Neighbors
Middlesex →Key facts
CEOJennifer A. Jarrett
SectorHealthcare
IndustryBiotechnology
HeadquartersWaltham, MA
ExchangeNASDAQ: DMRA
Employees7
IPO date2026-03-10
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.